Diffuse large B-cell lymphoma (DLBCL) is the predominant subtype of Non-Hodgkin lymphoma (NHL) in adolescents and adults. Originating from a B-cell lineage, the neoplastic cells typically express pan-B-cell antigens including CD19, CD20 and CD22. 1 DLBCL can be highly curable, particularly with localized disease. 2 Treatment with multi-agent chemotherapy+/-rituximab yields event-free survival rates of greater than 85% in all children and in adults with early stage disease only. However, for patients with refractory or relapsed disease, or adults with high stage disease, outcomes are poor and response to chemotherapy based salvage attempts are limited.